|
SPATA2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.97952765290665E-13 |
| Normal-vs-Stage3 |
1.62436730732907E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
3.574200E-01 |
| Stage1-vs-Stage3 |
1.993630E-02 |
| Stage1-vs-Stage4 |
5.409100E-04 |
| Stage2-vs-Stage3 |
6.822300E-03 |
| Stage2-vs-Stage4 |
5.557000E-04 |
| Stage3-vs-Stage4 |
2.162000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.46670470108279E-11 |
| Normal-vs-Asian |
1.62458935193399E-12 |
| Caucasian-vs-AfricanAmerican |
7.734600E-01 |
| Caucasian-vs-Asian |
2.347800E-01 |
| AfricanAmerican-vs-Asian |
6.175200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.298400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
1.74689999998812E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.606000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.823000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.141600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.179400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.383400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.624000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.11980449754878E-11 |
| Classical-VS-Follicular |
1.517990E-02 |
| Classical-VS-Other |
9.799600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
9.76880000003177E-07 |
| Tall-VS-Other |
1.019190E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
1.574010E-01 |
| Follicular-VS-Normal |
1.03159999986779E-07 |
| Other-VS-Normal |
1.72032999999905E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.40129999995453E-06 |
|
|
